A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)
Phase: PHASE2
Conditions: Chikungunya Virus Infection
Sponsor: Bavarian Nordic

ClinicalTrials.gov ID: NCT03483961 
Document: PXVX-CV-317-001 Protocol  
Protocol Title: A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and 
Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], unadjuvanted 
or alum-adjuvanted) 
Protocol Number: PXVX-CV-317-001 
Protocol Version 4.0  
Protocol Version Date: 22-May-2020 (Approval date: 27-May-2020)